Cargando…

Nasal spray (Zavegepant) for migraines: a mini-review

Neurological disorders, especially migraines, pose a significant global burden. This has driven the recent innovative research being conducted in the field of anti-migraine therapies, including the discovery of Zavegepant for the treatment of acute migraine attacks. Zavegepant is a novel, first-in-c...

Descripción completa

Detalles Bibliográficos
Autores principales: Larik, Muhammad Omar, Iftekhar, Muhammad Ashhal, Syed, Bilal Ulhassan, Ansari, Omema, Ansari, Mozaena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289569/
https://www.ncbi.nlm.nih.gov/pubmed/37363553
http://dx.doi.org/10.1097/MS9.0000000000000843
_version_ 1785062309085839360
author Larik, Muhammad Omar
Iftekhar, Muhammad Ashhal
Syed, Bilal Ulhassan
Ansari, Omema
Ansari, Mozaena
author_facet Larik, Muhammad Omar
Iftekhar, Muhammad Ashhal
Syed, Bilal Ulhassan
Ansari, Omema
Ansari, Mozaena
author_sort Larik, Muhammad Omar
collection PubMed
description Neurological disorders, especially migraines, pose a significant global burden. This has driven the recent innovative research being conducted in the field of anti-migraine therapies, including the discovery of Zavegepant for the treatment of acute migraine attacks. Zavegepant is a novel, first-in-class, intranasally administered calcitonin gene-related peptide (CGRP) receptor antagonist that has recently been approved for use in acute migraine attacks. Recent randomized controlled trials comparing Zavegepant with a placebo have demonstrated favorable results with respect to primary endpoints, as well as a desirable safety profile. The current first-line therapy consists of oral triptans, which are associated with lower efficacy, weaker safety profile, and an unsatisfactory preference rate among patients. Moreover, the intranasal method of administration is a characteristic advantage of Zavegepant, as patients suffering from acute migraine attacks cannot easily ingest oral medication, due to severe nausea and vomiting. In this mini-review, the efficacy and safety of Zavegepant will be compared with those of alternative treatments available for migraines, including oral triptans, intranasal triptans, and other CGRP antagonists currently available in the market. With currently available research, Zavegepant holds superiority over other forms of treatment and can be included in the current treatment guidelines for migraine attacks. However, further research is necessary to effectively assess Zavegepant’s long-term efficacy, safety, tolerability, and drug–drug interactions.
format Online
Article
Text
id pubmed-10289569
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-102895692023-06-24 Nasal spray (Zavegepant) for migraines: a mini-review Larik, Muhammad Omar Iftekhar, Muhammad Ashhal Syed, Bilal Ulhassan Ansari, Omema Ansari, Mozaena Ann Med Surg (Lond) Review Articles Neurological disorders, especially migraines, pose a significant global burden. This has driven the recent innovative research being conducted in the field of anti-migraine therapies, including the discovery of Zavegepant for the treatment of acute migraine attacks. Zavegepant is a novel, first-in-class, intranasally administered calcitonin gene-related peptide (CGRP) receptor antagonist that has recently been approved for use in acute migraine attacks. Recent randomized controlled trials comparing Zavegepant with a placebo have demonstrated favorable results with respect to primary endpoints, as well as a desirable safety profile. The current first-line therapy consists of oral triptans, which are associated with lower efficacy, weaker safety profile, and an unsatisfactory preference rate among patients. Moreover, the intranasal method of administration is a characteristic advantage of Zavegepant, as patients suffering from acute migraine attacks cannot easily ingest oral medication, due to severe nausea and vomiting. In this mini-review, the efficacy and safety of Zavegepant will be compared with those of alternative treatments available for migraines, including oral triptans, intranasal triptans, and other CGRP antagonists currently available in the market. With currently available research, Zavegepant holds superiority over other forms of treatment and can be included in the current treatment guidelines for migraine attacks. However, further research is necessary to effectively assess Zavegepant’s long-term efficacy, safety, tolerability, and drug–drug interactions. Lippincott Williams & Wilkins 2023-05-15 /pmc/articles/PMC10289569/ /pubmed/37363553 http://dx.doi.org/10.1097/MS9.0000000000000843 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (https://creativecommons.org/licenses/by/4.0/) (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Review Articles
Larik, Muhammad Omar
Iftekhar, Muhammad Ashhal
Syed, Bilal Ulhassan
Ansari, Omema
Ansari, Mozaena
Nasal spray (Zavegepant) for migraines: a mini-review
title Nasal spray (Zavegepant) for migraines: a mini-review
title_full Nasal spray (Zavegepant) for migraines: a mini-review
title_fullStr Nasal spray (Zavegepant) for migraines: a mini-review
title_full_unstemmed Nasal spray (Zavegepant) for migraines: a mini-review
title_short Nasal spray (Zavegepant) for migraines: a mini-review
title_sort nasal spray (zavegepant) for migraines: a mini-review
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289569/
https://www.ncbi.nlm.nih.gov/pubmed/37363553
http://dx.doi.org/10.1097/MS9.0000000000000843
work_keys_str_mv AT larikmuhammadomar nasalsprayzavegepantformigrainesaminireview
AT iftekharmuhammadashhal nasalsprayzavegepantformigrainesaminireview
AT syedbilalulhassan nasalsprayzavegepantformigrainesaminireview
AT ansariomema nasalsprayzavegepantformigrainesaminireview
AT ansarimozaena nasalsprayzavegepantformigrainesaminireview